Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT), a biopharmaceutical company focused on gastrointestinal diseases, has announced it will host a live webcast on Thursday, August 8, 2024, at 8:30 am ET to report its second quarter 2024 financial results and provide a business update. The webcast will be accessible on the company's website and will be available for 90 days following the event.

Phathom specializes in developing and commercializing novel treatments for gastrointestinal diseases. The company has exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the US as VOQUEZNA® for various GERD-related treatments and VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment in adults.

Positive

• Phathom has exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB)
• VOQUEZNA® is already marketed in the US for various GERD-related treatments
• The company has developed VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment

Negative

• None.

• Management to host conference call on Thursday, August 8, 2024, at 8:30 am ET
  
  

FLORHAM PARK, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, August 8, 2024, to report its second quarter 2024 financial results and provide an update on business progress.

A live webcast and additional information about the presentation can be accessed on the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2024 Phathom Pharmaceuticals. All rights reserved.

FAQ

When will Phathom Pharmaceuticals (PHAT) report its Q2 2024 financial results?

Phathom Pharmaceuticals (PHAT) will report its second quarter 2024 financial results on Thursday, August 8, 2024, during a live webcast at 8:30 am ET.

What is Phathom Pharmaceuticals' (PHAT) main product?

Phathom Pharmaceuticals' (PHAT) main product is vonoprazan, marketed as VOQUEZNA®, a first-in-class potassium-competitive acid blocker (PCAB) for treating various GERD-related conditions and H. pylori infections in adults.

How long will the recording of Phathom Pharmaceuticals' (PHAT) Q2 2024 webcast be available?

The recording of Phathom Pharmaceuticals' (PHAT) Q2 2024 financial results webcast will be available for 90 days following the conclusion of the meeting.

What are the indications for VOQUEZNA® by Phathom Pharmaceuticals (PHAT)?

VOQUEZNA® by Phathom Pharmaceuticals (PHAT) is indicated for treating heartburn associated with Non-Erosive GERD, healing and maintenance of healing of Erosive GERD, and associated heartburn in adults.